secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001140361-26-019761
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Pharma establishes $500M at-the-market equity offering program
------------------------------------------------------------------------

- Up to $500M in common stock may be sold via ATM through Goldman Sachs and Leerink Partners.
- Sales agents will receive up to 3.0% commission on gross proceeds; company not obligated to sell.
- Prior May 2023 equity distribution agreement terminated in conjunction with new facility.
- Registration statement on Form S-3ASR filed to support the offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126019761/0001140361-26-019761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126019761/ny20072667x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-019761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer